MX2020011816A - Metodo para purificar la neurotoxina clostridial. - Google Patents
Metodo para purificar la neurotoxina clostridial.Info
- Publication number
- MX2020011816A MX2020011816A MX2020011816A MX2020011816A MX2020011816A MX 2020011816 A MX2020011816 A MX 2020011816A MX 2020011816 A MX2020011816 A MX 2020011816A MX 2020011816 A MX2020011816 A MX 2020011816A MX 2020011816 A MX2020011816 A MX 2020011816A
- Authority
- MX
- Mexico
- Prior art keywords
- clostridial neurotoxin
- contacting
- clostridial
- purifying
- neurotoxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método para purificar una neurotoxina clostridial que comprende poner en contacto una resina de intercambio catiónico con una composición que comprende una neurotoxina clostridial, donde la etapa de contacto se realiza al menos pH 7.3, donde se produce la etapa de poner en contacto una resina de intercambio catiónico con una composición que comprende la neurotoxina clostridial antes de la conversión de la neurotoxina clostridial de una forma monocatenaria en una forma bicatenaria. También se proporcionan usos de una solución amortiguadora que tiene un valor de pH que es -1 unidad de pH o superior al pI calculado de una neurotoxina clostridial, intermediarios de purificación y neurotoxinas clostridiales obtenibles por la invención, en donde la neurotoxina clostridial está en una forma monocatenaria.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1517450.1A GB201517450D0 (en) | 2015-10-02 | 2015-10-02 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011816A true MX2020011816A (es) | 2021-01-15 |
Family
ID=54606010
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003644A MX2018003644A (es) | 2015-10-02 | 2016-09-27 | Metodo para purificar la neurotoxina clostridial. |
| MX2020011816A MX2020011816A (es) | 2015-10-02 | 2018-03-23 | Metodo para purificar la neurotoxina clostridial. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003644A MX2018003644A (es) | 2015-10-02 | 2016-09-27 | Metodo para purificar la neurotoxina clostridial. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11066451B2 (es) |
| EP (2) | EP3650462A1 (es) |
| JP (1) | JP2018537412A (es) |
| KR (1) | KR102675034B1 (es) |
| CN (1) | CN108137657A (es) |
| AU (1) | AU2016330322A1 (es) |
| BR (1) | BR112018006300A2 (es) |
| CA (1) | CA2996695A1 (es) |
| DK (1) | DK3356391T3 (es) |
| EA (1) | EA036610B1 (es) |
| ES (1) | ES2769775T3 (es) |
| GB (1) | GB201517450D0 (es) |
| HK (2) | HK1255471A1 (es) |
| HU (1) | HUE047489T2 (es) |
| MX (2) | MX2018003644A (es) |
| PL (1) | PL3356391T3 (es) |
| PT (1) | PT3356391T (es) |
| SG (1) | SG10202001084VA (es) |
| WO (1) | WO2017055274A1 (es) |
| ZA (1) | ZA201801755B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365496B (es) * | 2009-10-21 | 2019-06-05 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| AU2021238924A1 (en) | 2020-03-16 | 2022-08-25 | Ipsen Biopharm Limited | Modified botulinum neurotoxin for treating limb spasticity |
| CN113832069B (zh) * | 2020-11-30 | 2024-01-30 | 河南农业大学 | 丁酸梭菌及其应用 |
| JP2024513191A (ja) * | 2021-03-30 | 2024-03-22 | イプセン バイオファーム リミテッド | 疼痛及び炎症性障害の処置 |
| EP4401759A1 (en) | 2021-09-16 | 2024-07-24 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of cervical dystonia |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| EP4404955A1 (en) | 2021-09-23 | 2024-07-31 | Ipsen Biopharm Limited | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
| KR20240051355A (ko) * | 2022-10-12 | 2024-04-22 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
| ES2168302T3 (es) | 1993-06-10 | 2002-06-16 | Allergan Inc | Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e. |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| CA2331274C (en) | 1998-05-13 | 2010-04-06 | Biotecon Gesellschaft Fur Biotechnologische Entwicklung Und Consulting Mbh | Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof |
| CA2335105C (en) | 1998-07-22 | 2010-05-11 | Osprey Pharmaceuticals Limited | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| US6358697B2 (en) | 1999-04-21 | 2002-03-19 | Children's Hospital Medical Center | Intracellular pharmaceutical targeting |
| US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| EP2267010B1 (en) | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Activatable recombinant neurotoxins |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US7273722B2 (en) | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
| ITBO20010426A1 (it) * | 2001-07-06 | 2003-01-06 | Alfa Wassermann Spa | Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| CA2501856A1 (en) | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
| US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| CN1616489A (zh) * | 2004-09-30 | 2005-05-18 | 中国科学技术大学 | 纯化重组人白细胞介素12的方法 |
| AU2005311086B2 (en) | 2004-12-01 | 2012-03-29 | Allergan, Inc. | Fusion proteins |
| CA2556796C (en) | 2005-03-03 | 2018-01-23 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| DK2154151T3 (da) | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| BRPI1008885B1 (pt) * | 2009-02-19 | 2021-09-28 | Merz Pharma Gmbh & Co. Kgaa | Método para obter uma solução purificada de polipeptídeos de neurotoxina processados e composição |
| GB0903006D0 (en) | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| CN101497909B (zh) * | 2009-03-05 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | 制备抗a型肉毒毒素免疫球蛋白抗体的方法 |
| EP2419128B1 (en) | 2009-04-14 | 2018-06-06 | Medical College of Wisconsin, Inc. | Engineered botulinum neurotoxin |
| US8440204B2 (en) | 2009-04-30 | 2013-05-14 | Wisconsin Alumni Research Foundation | Subtype of Closteridium botulinum neurotoxin type A and uses thereof |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| MX365496B (es) * | 2009-10-21 | 2019-06-05 | Revance Therapeutics Inc | Metodos y sistemas para purificar la neurotoxina botulinica no acomplejada. |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| WO2013091895A1 (en) * | 2011-12-23 | 2013-06-27 | Merz Pharma Gmbh & Co. Kgaa | Novel method for the manufacturing of di-chain proteins for use in humans |
| KR20180077343A (ko) * | 2012-11-21 | 2018-07-06 | 입센 바이오이노베이션 리미티드 | 단백질 가수분해 처리된 폴리펩티드의 제조방법 |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| WO2016110662A1 (en) | 2015-01-09 | 2016-07-14 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
-
2015
- 2015-10-02 GB GBGB1517450.1A patent/GB201517450D0/en not_active Ceased
-
2016
- 2016-09-27 AU AU2016330322A patent/AU2016330322A1/en not_active Abandoned
- 2016-09-27 CN CN201680055073.8A patent/CN108137657A/zh active Pending
- 2016-09-27 WO PCT/EP2016/072986 patent/WO2017055274A1/en active Application Filing
- 2016-09-27 EP EP19198429.3A patent/EP3650462A1/en active Pending
- 2016-09-27 PT PT167848027T patent/PT3356391T/pt unknown
- 2016-09-27 EA EA201890851A patent/EA036610B1/ru unknown
- 2016-09-27 DK DK16784802.7T patent/DK3356391T3/da active
- 2016-09-27 KR KR1020187011891A patent/KR102675034B1/ko active IP Right Grant
- 2016-09-27 EP EP16784802.7A patent/EP3356391B1/en active Active
- 2016-09-27 BR BR112018006300-2A patent/BR112018006300A2/pt not_active Application Discontinuation
- 2016-09-27 HU HUE16784802A patent/HUE047489T2/hu unknown
- 2016-09-27 MX MX2018003644A patent/MX2018003644A/es unknown
- 2016-09-27 ES ES16784802T patent/ES2769775T3/es active Active
- 2016-09-27 JP JP2018517224A patent/JP2018537412A/ja active Pending
- 2016-09-27 US US15/765,427 patent/US11066451B2/en active Active
- 2016-09-27 CA CA2996695A patent/CA2996695A1/en not_active Abandoned
- 2016-09-27 PL PL16784802T patent/PL3356391T3/pl unknown
- 2016-09-27 SG SG10202001084VA patent/SG10202001084VA/en unknown
-
2018
- 2018-03-14 ZA ZA2018/01755A patent/ZA201801755B/en unknown
- 2018-03-23 MX MX2020011816A patent/MX2020011816A/es unknown
- 2018-11-15 HK HK18114645.0A patent/HK1255471A1/zh unknown
-
2019
- 2019-01-04 HK HK19100138.2A patent/HK1257762A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180080205A (ko) | 2018-07-11 |
| PT3356391T (pt) | 2020-02-19 |
| CA2996695A1 (en) | 2017-04-06 |
| HUE047489T2 (hu) | 2020-04-28 |
| WO2017055274A1 (en) | 2017-04-06 |
| HK1257762A1 (zh) | 2019-10-25 |
| DK3356391T3 (da) | 2020-02-03 |
| BR112018006300A2 (pt) | 2018-10-16 |
| AU2016330322A1 (en) | 2018-04-26 |
| GB201517450D0 (en) | 2015-11-18 |
| EA201890851A1 (ru) | 2018-08-31 |
| SG10202001084VA (en) | 2020-03-30 |
| US11066451B2 (en) | 2021-07-20 |
| JP2018537412A (ja) | 2018-12-20 |
| KR102675034B1 (ko) | 2024-06-14 |
| EP3650462A1 (en) | 2020-05-13 |
| HK1255471A1 (zh) | 2019-08-16 |
| PL3356391T3 (pl) | 2020-07-27 |
| EP3356391B1 (en) | 2019-11-06 |
| EP3356391A1 (en) | 2018-08-08 |
| MX2018003644A (es) | 2018-04-30 |
| ES2769775T3 (es) | 2020-06-29 |
| ZA201801755B (en) | 2019-01-30 |
| CN108137657A (zh) | 2018-06-08 |
| EA036610B1 (ru) | 2020-11-30 |
| US20190100564A1 (en) | 2019-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011816A (es) | Metodo para purificar la neurotoxina clostridial. | |
| MX2018005829A (es) | Composiciones para tratar el cabello. | |
| PH12020550529A1 (en) | Recombinant bacterium capable of producing l-lysine, construction method thereof and production method of l-lysine | |
| MX2021006714A (es) | Neurotoxinas cationicas. | |
| EP3708660A3 (en) | Polypeptides | |
| PH12017502215A1 (en) | Recombinant microorganism for improve production of fine chemicals | |
| MY189932A (en) | Recombinant microorganism for improved production of alanine | |
| MY181068A (en) | Recombinant microorganism for improved production of fine chemicals | |
| EP3162894A3 (en) | Methods for the manufacture of proteolytically processed polypeptides | |
| MX2019011554A (es) | Purificacion de ficobiliproteinas. | |
| PH12017501678A1 (en) | Recombinant microorganism for improved production of finie chemicals | |
| PH12018500150A1 (en) | Microorganisms for producing putrescine or ornithine and process for producing putrescine or ornithine using them | |
| MY187636A (en) | Pyruvate dehydrogenase variants, a microorganism comprising the same and a method for producing l-amino acid using the same | |
| EA201890710A1 (ru) | Способ очистки гидролизата биомассы | |
| MY176584A (en) | Gluconate repressor variant, microorganism containing the same producing l-lysine, and method for producing l-lysine | |
| MY193587A (en) | Genetically modified microorganism for improved production of fine chemicals on sucrose | |
| PH12018500069A1 (en) | Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same | |
| UA114997C2 (uk) | Рекомбінантний мікроорганізм з роду escherichia, що виробляє l-амінокислоту, та спосіб одержання l-амінокислоти | |
| MY193588A (en) | Improved microorganisms for succinic acid production | |
| EA201692327A1 (ru) | Пролин-специфическая эндопротеаза | |
| MY174840A (en) | Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same | |
| EA201991474A1 (ru) | Способы получения фитоина | |
| MY180044A (en) | Microorganism with enhanced l-lysine producibility and method for producing l-lysine using the same | |
| BR112017020057A2 (pt) | novo método para promover nodulação em plantas | |
| TH1601003427A (th) | จุลินทรีย์รีคอมบิแนนท์สำหรับการผลิตที่เพิ่มของสารเคมี |